Explore the words cloud of the ChiLTERN project. It provides you a very rough idea of what is the project "ChiLTERN" about.
The following table provides information about the project.
THE UNIVERSITY OF BIRMINGHAM
|Coordinator Country||United Kingdom [UK]|
|Total cost||8˙191˙665 €|
|EC max contribution||7˙941˙665 € (97%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-01-01 to 2020-12-31|
Take a look of project's partnership.
|1||THE UNIVERSITY OF BIRMINGHAM||UK (BIRMINGHAM)||coordinator||3˙127˙320.00|
|2||INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL||ES (BADALONA BARCELONA)||participant||990˙456.00|
|3||LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN||DE (MUENCHEN)||participant||702˙250.00|
|4||CENTRE HOSPITALIER UNIVERSITAIRE DE RENNES||FR (RENNES CEDEX 9)||participant||472˙356.00|
|5||EBERHARD KARLS UNIVERSITAET TUEBINGEN||DE (TUEBINGEN)||participant||406˙250.00|
|6||CINECA CONSORZIO INTERUNIVERSITARIO||IT (CASALECCHIO DI RENO BO)||participant||281˙250.00|
|7||CLINIQUES UNIVERSITAIRES SAINT-LUC||BE (BRUXELLES)||participant||236˙402.00|
|8||UNIVERSITATSKLINIKUM BONN||DE (BONN)||participant||230˙500.00|
|9||SERVICIO ANDALUZ DE SALUD||ES (SEVILLA)||participant||187˙575.00|
|10||GDANSKI UNIWERSYTET MEDYCZNY||PL (GDANSK)||participant||181˙425.00|
|11||AZIENDA OSPEDALIERA DI PADOVA||IT (PADOVA)||participant||177˙275.00|
|12||ISTITUTO DI RICERCA PEDIATRICA CITTA DELLA SPERANZA||IT (PADOVA)||participant||130˙000.00|
|13||CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL||DE (KIEL)||participant||121˙875.00|
|14||VASTRA GOTALANDS LANS LANDSTING||SE (VANERSBORG)||participant||117˙825.00|
|15||OSLO UNIVERSITETSSYKEHUS HF||NO (OSLO)||participant||107˙387.00|
|16||UNIVERSITA DEGLI STUDI DI PADOVA||IT (PADOVA)||participant||105˙625.00|
|17||OUR LADYS CHILDRENS HOSPITAL CRUMLIN||IE (DUBLIN)||participant||92˙262.00|
|18||UNIVERSITY OF NEWCASTLE UPON TYNE||UK (NEWCASTLE UPON TYNE)||participant||87˙655.00|
|19||MEVIS MEDICAL SOLUTIONS AG||DE (BREMEN)||participant||75˙000.00|
|20||PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV||NL (UTRECHT)||participant||48˙000.00|
|21||FAKULTNI NEMOCNICE V MOTOLE||CZ (PRAHA 5)||participant||36˙725.00|
|22||XENTECH SAS||FR (Evry)||participant||26˙250.00|
|23||SCHWEIZERISCHE PADIATRISCHE ONKOLOGIE GRUPPE (SPOG)||CH (BERN)||participant||0.00|
Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in the childhood population is hepatoblastoma (HB), usually seen in young children and infants. Much rarer (about 10% of paediatric liver cancers) is hepatocellular carcinoma (HCC), usually seen in the teenage population and sometimes associated with underlying cirrhotic liver diseases. The ChiLTERN project relates to topic PHC 18 ‘establishing effectiveness of health care interventions in the paediatric population’. The ChiLTERN project builds on a unique opportunity to undertake a comprehensive research programme linked to an ambitious global partnership which will see the single largest clinical trial (the Paediatric Hepatic International Tumour Trial - PHITT) ever undertaken in this population of patients, with several randomised questions in six subgroups of patients. ChiLTERN will allow us to move towards an era of personalised therapy in which each patient will receive the correct amount of chemotherapy and will undergo has the best surgical operation (surgical resection or liver transplant). By using both clinical and biological information, we can assign patients more accurately to risk groups based on their survival. Using genetic tests and biomarkers, we will determine those children who may be at risk of developing long term side effects (deafness, heart failure, kidney damage). In addition, biomarkers will allow us to monitor during therapy and detect toxicities early before serious damage is done so that we can adapt treatment and prevent these problems. Finally, we will be using imaging technology tools which will help our surgeons plan liver operations more safely and effectively. Ultimately ChiLTERN will allow us to cure more children with liver cancer, expose fewer children to toxic chemotherapy and ensure their surgery is both effective and safe.
|Publication Policy||Documents, reports||2020-04-07 20:37:05|
|Registration in ISRCTN||Websites, patent fillings, videos etc.||2020-04-07 20:37:05|
|Protocols for standardised collection of clinical samples and sample analysis||Documents, reports||2020-04-07 20:37:05|
|Project Data Management Plan||Documents, reports||2020-04-07 20:37:05|
|Dissemination and Communication Plan: and updated regularly||Documents, reports||2020-04-07 20:37:05|
|Protocol finalisation and submission to EC.||Documents, reports||2020-04-07 20:37:05|
|Project Management||Documents, reports||2020-04-07 20:37:04|
|Website activation||Websites, patent fillings, videos etc.||2020-04-07 20:37:05|
Take a look to the deliverables list in detail: detailed list of ChiLTERN deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHILTERN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CHILTERN" are provided by the European Opendata Portal: CORDIS opendata.
Collaboration for innovation: Establishment of a pan-nematode drug development platformRead More
Global Alliance for Chronic Diseases SecretariatRead More
Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccinationRead More